Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the Republic of South Korea

PHASE4CompletedINTERVENTIONAL
Enrollment

3,948

Participants

Timeline

Start Date

March 15, 2013

Primary Completion Date

January 22, 2018

Study Completion Date

January 22, 2018

Conditions
Meningococcal Disease
Interventions
BIOLOGICAL

MenACWY-CRM (Menveo)

One dose administered intramuscularly preferably into the anterolateral aspect of the thigh in infants or into the deltoid muscle in children, adolescents and adults.

Trial Locations (54)

10503

GSK Investigational Site, Goyang-si, Gyeonggi-do

10589

GSK Investigational Site, Goyang-si

11440

GSK Investigational Site, Yangju-si, Gyeonggi-do

14250

GSK Investigational Site, Gwangmyeong

14610

GSK Investigational Site, Bucheon-si

15381

GSK Investigational Site, Ansan

16481

GSK Investigational Site, Gyeonggi-do

22214

GSK Investigational Site, Incheon

22397

GSK Investigational Site, Incheon

22736

GSK Investigational Site, Incheon

25768

GSK Investigational Site, Donghae

34189

GSK Investigational Site, Daejeon

34944

GSK Investigational Site, Daejeon

51004

GSK Investigational Site, Gimhae

51503

GSK Investigational Site, Changwon

63070

GSK Investigational Site, Jeju City

110746

GSK Investigational Site, Seoul

135720

GSK Investigational Site, Seoul

135951

GSK Investigational Site, Seoul

138201

GSK Investigational Site, Seoul

143729

GSK Investigational Site, Seoul

152703

GSK Investigational Site, Guro Gu

156755

GSK Investigational Site, Seoul

530822

GSK Investigational Site, Jeollanam Do

683380

GSK Investigational Site, Ulsan

431 062

GSK Investigational Site, Anyang

Unknown

GSK Investigational Site, Busan

GSK Investigational Site, Gyeonggi-do

GSK Investigational Site, Kyeonggido

GSK Investigational Site, Seoul

GSK Investigational Site, Ulsan

706 090

GSK Investigational Site, Daegu

484 5

GSK Investigational Site, Gwangmyeong

158 774

GSK Investigational Site, Gyeonggi-do

463 707

GSK Investigational Site, Gyeonggi-do

450 832

GSK Investigational Site, Pyeongtaek-si

02598

GSK Investigational Site, Seoul

02717

GSK Investigational Site, Seoul

03966

GSK Investigational Site, Seoul

04143

GSK Investigational Site, Seoul

04154

GSK Investigational Site, Seoul

04168

GSK Investigational Site, Seoul

06591

GSK Investigational Site, Seoul

100 032

GSK Investigational Site, Seoul

130 702

GSK Investigational Site, Seoul

130-702

GSK Investigational Site, Seoul

130-711

GSK Investigational Site, Seoul

132-703

GSK Investigational Site, Seoul

135 244

GSK Investigational Site, Seoul

137 873

GSK Investigational Site, Seoul

138 162

GSK Investigational Site, Seoul

140 887

GSK Investigational Site, Seoul

156-070

GSK Investigational Site, Seoul

158 885

GSK Investigational Site, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01766206 - Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the Republic of South Korea | Biotech Hunter | Biotech Hunter